Belgium shows exceptional results in terms of innovation and industrial development, especially in the field of biopharmaceuticals. The following figures give ample evidence of this :
- the largest number of medicines in development in the world per capita
- the highest number of phase 1 clinical trials in Europe per capita & highest number of phases 1 to 3 clinical trials per capita
- the highest concentration of life-science employees in the world
- the second largest pharmaceutical export country in the world in absolute figures
- the 7th largest investor in the world in biopharmaceutical R&D
Furthermore, Belgium offers major advantages for potential investment and career opportunities. These make of Belgium a center of excellence in biopharmacy.
This website aims to illustrate the many reasons why Belgium is “the place to be for biopharmaceutical R&D and manufacturing”.
As a potential investor, you will also find on this website a list of biopharmaceutical companies active in Belgium, news from the Belgian biopharma industry, an agenda of leading missions, fairs and conferences in which we will participate, plus a network of public and private organizations to which you can refer to help guide your choice of investments.
Major breakthroughs in Belgian biopharma For the most important global pandemics - HIV/Aids, tuberculosis and malaria - major breakthroughs were achieved both in vaccines and pharmaceutical drugs by Belgian-based industry laboratories in recent years. These complement the already substantial successes in the discovery of compounds against infectious diseases and others such as schizophrenia, epilepsy, cancer drugs and immunotherapy and immune deficiency. The country is also a world center of vaccines research and manufacturing, with several worldwide first historic results and also new vaccines for the prevention of cervical cancer, rotavirus, flu pre-pandemic and pandemic, and many more. |